Atopic dermatitis in dogs: antihistamines vs placebo for pruritus — MAYBE (weak evidence)

In dogs with atopic dermatitis, do antihistamines (cetirizine, hydroxyzine, chlorpheniramine) vs placebo reduce pruritus?

Shelf #278 · gate-verified and displayed under the developer's blinded-trial rule

MAYBE (weak evidence): The controlled evidence is thin, small and split — and for cetirizine, the best-tested drug, it is null. Hsiao 2016, a randomized, double blind, placebo-controlled trial in 50 dogs with chronic atopic dermatitis meeting Favrot's criteria, found cetirizine 3 mg/kg once daily for 14 days clearly had no effect on pruritus, with no significant difference between groups; the smaller single-blinded placebo-controlled crossover of Cook 2004 points the same way (pruritus satisfactorily reduced in only 4/22 dogs, 18%, on cetirizine). Against that, one small double-blinded placebo-controlled crossover (Eichenseer 2013, 19 dogs) found the hydroxyzine/chlorpheniramine combination significantly improved both lesion scores (P=0.049) and pruritus (P=0.05), with more than 25% pruritus improvement in 10/17 dogs on the combination vs 2/19 on placebo — a real but fragile signal from 19 dogs, at borderline significance, over 14-day periods. The 2001 ACVD task force review (DeBoer & Griffin) had already found that most published studies were open and uncontrolled, reporting 0 to 75% efficacy for the same drugs, and that the few blinded placebo-controlled trials then available had failed to confirm efficacy. Nothing since overturns that verdict for cetirizine; the combination result keeps the class at MAYBE (weak evidence) rather than a flat no. Drafted Nov 10, 2026 (VetMed build, topic #278); all figures from abstracts fetched and verified at drafting.

Hsiao 2016: cetirizine 3 mg/kg for 14 days clearly had NO effect on pruritus in chronic atopic dermatitis — no significant difference vs placebo

Randomized, double blind, placebo-controlled trial (record's own wording and publication type)

Who: Dogs: dogs with chronic atopic dermatitis fulfilling Favrot's diagnostic clinical criteria, in a clinical setting; dogs received either cetirizine 3 mg/kg (n = 27) or placebo (n = 23) orally once daily for 14 days, without concomitant medication, with pruritus assessed by visual analog scale at day 0 and day 14.

Result: After 14 days, cetirizine clearly had no effect on the pruritus in dogs with chronic atopic dermatitis, and there was no significant difference between groups. The authors concluded that cetirizine (and likely H1 histamine receptor antagonists in general) should not be recommended for the control of pruritus in dogs with long term allergies.

Watch out: This is the largest and cleanest test on the shelf (50 dogs, double blind, placebo-controlled, standardised diagnosis, no concomitant medication) and its primary result was null — for cetirizine the stamp logic would on its own support 'the treatment made no difference'; the shelf stamp stays MAYBE (weak evidence) because the hydroxyzine/chlorpheniramine combination card below points the other way. Fourteen days is short, a single dose level (3 mg/kg) was tested, and the authors' generalisation from cetirizine to all H1 antagonists goes beyond what one drug's trial can show — the record's own conclusion is reported as the authors', not adopted here for the whole class.

Hsiao YH, Chen C, Willemse T. Effects of cetirizine in dogs with chronic atopic dermatitis: a randomized, double blind, placebo-controlled trial. J Vet Sci. 2016;17(4):549-553. PMID: 27297415. Registry ID: none in the record. MeSH: Animals · Cetirizine/therapeutic use · Chronic Disease · Dermatitis, Atopic/drug therapy,etiology,veterinary · Dog Diseases/drug therapy,etiology · Dogs · Double-Blind Method · Female · Histamine H1 Antagonists, Non-Sedating/therapeutic use · Male · Treatment Outcome

Cook 2004: cetirizine satisfactorily reduced pruritus in only 4/22 dogs (18%) that completed the trial; two dogs vomited on the active drug

Single-blinded, placebo-controlled study (record's own title wording; crossover and random allocation indexed in MeSH)

Who: Dogs: 23 dogs with atopic dermatitis in a clinical setting; cetirizine and placebo were administered orally as individual agents (crossover design as indexed in the record), and 22 dogs completed the trial.

Result: The pruritus was satisfactorily reduced in 4/22 (18%) dogs that completed the trial with cetirizine. Two dogs vomited after administration of the active drug.

Watch out: A very short record: the abstract reports the cetirizine responder count but no corresponding placebo responder count and no statistical comparison, so no placebo-adjusted effect can be calculated from the record — the 18% figure is carded exactly as reported and must not be read as 18% better than placebo. Single-blinded (the record does not specify who was blinded), 23 dogs enrolled, and 'satisfactorily reduced' is the authors' judgement threshold. It is consistent with Hsiao 2016's null result but far weaker on its own.

Cook CP, Scott DW, Miller WH Jr, Kirker JE, Cobb SM. Treatment of canine atopic dermatitis with cetirizine, a second generation antihistamine: a single-blinded, placebo-controlled study. Can Vet J. 2004;45(5):414-7. PMID: 15206590. Registry ID: none in the record. MeSH: Administration, Oral · Animals · Cetirizine/adverse effects,therapeutic use · Cross-Over Studies · Dermatitis, Atopic/drug therapy,veterinary · Dog Diseases/drug therapy · Dogs · Female · Histamine H1 Antagonists, Non-Sedating/adverse effects,therapeutic use · Male · Placebos · Pruritus/drug therapy,veterinary · Random Allocation · Single-Blind Method · Treatment Outcome · Vomiting/chemically induced,veterinary

Eichenseer 2013: hydroxyzine/chlorpheniramine improved CADESI (P=0.049) and pruritus (P=0.05); over-25% itch improvement in 10/17 dogs vs 2/19 on placebo

Randomised, controlled, double-blinded, placebo-controlled cross-over trial (record's own wording and publication type)

Who: Dogs: 19 dogs with atopic dermatitis in a clinical setting; each dog was treated with dimetinden, a combination of chlorpheniramine and hydroxyzine, or placebo, orally for 14 days per period, each period followed by a 14-day washout; the Canine Atopic Dermatitis Extent and Severity Index (CADESI) was determined by a clinician and pruritus and general condition by the owner before and after each period.

Result: Dimetinden improved the pruritus significantly (P=0.014) but not the CADESI (P=0.087); the combination of hydroxyzine and chlorpheniramine improved the CADESI (P=0.049) and pruritus (P=0.05) significantly. Ten of 17 dogs improved by more than 25 per cent in pruritus with the combination of hydroxyzine and chlorpheniramine, 12 of 18 with dimetindenmaleate and only 2 of 19 with placebo. The authors concluded that antihistamines can help to reduce pruritus in atopic dogs, but that in most cases the improvement is limited and additional treatment may be needed.

Watch out: The one positive controlled result on this shelf rests on 19 dogs in a crossover with 14-day treatment periods: the combination's pruritus P value sits exactly at 0.05 and its CADESI P value at 0.049, so a dog or two changing category would erase significance, and differing denominators (17, 18 and 19 dogs across periods) show incomplete periods. Dimetinden, the trial's other active arm, is not one of the drugs named in this shelf's question and is reported here only because it shares the record; the card's claim rests on the hydroxyzine/chlorpheniramine combination arm. Hydroxyzine and chlorpheniramine were tested only as a fixed combination, so the record cannot say which drug, if either alone, did the work.

Eichenseer M, Johansen C, Mueller RS. Efficacy of dimetinden and hydroxyzine/chlorpheniramine in atopic dogs: a randomised, controlled, double-blinded trial. Vet Rec. 2013;173(17):423. PMID: 24114734. Registry ID: none in the record. MeSH: Animals · Antipruritics/therapeutic use · Chlorpheniramine/therapeutic use · Cross-Over Studies · Dermatitis, Atopic/drug therapy,veterinary · Dimethindene/therapeutic use · Dog Diseases/drug therapy · Dogs · Double-Blind Method · Drug Therapy, Combination/veterinary · Female · Hydroxyzine/therapeutic use · Male · Treatment Outcome

DeBoer & Griffin 2001 (context): most antihistamine studies were open and uncontrolled (reported efficacy 0 to 75%); the few blinded placebo-controlled trials had failed to confirm efficacy

Review — ACVD task force critical review (record's own publication types; context card, not a trial)

Who: Dogs: a critical review of the published literature on antihistamine use in canine atopic dermatitis, prepared for the American College of Veterinary Dermatology task force on canine atopic dermatitis (context card — no new animals enrolled).

Result: The majority of published, peer-reviewed studies were open, uncontrolled or partially-controlled trials, varying widely in reported efficacy, from perhaps 0 to 75% of patients, even using the same drug. The few blinded placebo-controlled trials available had failed to confirm efficacy of these drugs to relieve the pruritus of canine atopic dermatitis. Some studies indicated synergistic effects could occur with concurrent use of essential fatty acid supplements. The authors concluded there was insufficient evidence to conclude for or against the efficacy of antihistamines for treatment of canine atopic dermatitis, that additional blinded, randomized and controlled trials with larger numbers of patients were necessary, and that clinician consensus nonetheless suggested evaluating several different antihistamine drugs in sequence, for 7–14 days each, in canine patients with atopic dermatitis.

Watch out: CONTEXT ONLY — this is a 2001 narrative task-force review, not a trial, and it carries no figures of its own beyond the 0 to 75% range it reports across the uncontrolled literature; that range is quoted as the review's characterisation, not as an effect estimate. It is carded because it is the draft anchor for this shelf and because it explains why the uncontrolled evaluations behind everyday antihistamine use cannot carry the claim: in uncontrolled atopic dermatitis trials, spontaneous fluctuation and owner expectation alone can produce response rates anywhere in that range. Its 'insufficient evidence' verdict predates Hsiao 2016 and Eichenseer 2013, which are carded above on their own records.

DeBoer DJ, Griffin CE. The ACVD task force on canine atopic dermatitis (XXI): antihistamine pharmacotherapy. Vet Immunol Immunopathol. 2001;81(3-4):323-9. PMID: 11553395. Registry ID: none in the record. MeSH: Animals · Anti-Allergic Agents/therapeutic use · Dermatitis, Atopic/drug therapy,veterinary · Dog Diseases/drug therapy · Dogs · Histamine H1 Antagonists/therapeutic use · Humans · Societies, Medical · United States

Synthesis: cetirizine has failed its controlled tests; a hydroxyzine/chlorpheniramine combination helped in one tiny crossover — the class answer is 'unproven, probably little'

Synthesis

Who: Synthesis of the cards above: Hsiao 2016 (50 dogs with chronic atopic dermatitis, randomized, double blind, placebo-controlled), Cook 2004 (23 dogs, single-blinded, placebo-controlled crossover), Eichenseer 2013 (19 dogs, double-blinded, placebo-controlled crossover) and DeBoer & Griffin 2001 (ACVD task force critical review, context).

Result: Read by drug rather than by class: (1) cetirizine — no benefit shown in either controlled test (no significant difference in the 50-dog double-blind trial; satisfactory itch reduction in only 4/22 dogs in the single-blinded study); (2) hydroxyzine + chlorpheniramine in combination — statistically significant but borderline improvements in itch and lesion scores in one 19-dog crossover, with over-25% itch improvement in 10/17 dogs vs 2/19 on placebo; (3) the pre-2001 uncontrolled literature, reporting 0 to 75% efficacy for the same drugs, is exactly the kind of evidence that cannot settle the question, as the task force review itself concluded. A larger confirmatory trial of the combination — or of hydroxyzine or chlorpheniramine alone against placebo — is what this shelf still lacks.

Watch out: All controlled trials here are short (14 days per treatment in Hsiao and Eichenseer) and small; none tests hydroxyzine or chlorpheniramine as a single agent against placebo, and none addresses long-term or seasonal use. Sedation and other adverse effects are barely reported in these records (two dogs vomited on cetirizine in Cook 2004) — absence of reporting is not evidence of absence of harm.

Synthesis of Hsiao YH et al. PMID: 27297415; Cook CP et al. PMID: 15206590; Eichenseer M et al. PMID: 24114734; DeBoer DJ, Griffin CE. PMID: 11553395. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.